RA
MIRM icon

RiverPark Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

RiverPark Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186K Buy
2,014
+282
+16% +$26.5K 0.07% 90
2025
Q4 		$137K Buy
1,732
+77
+5% +$5.53K 0.04% 101
2025
Q3 		$121K Buy
+1,655
New +$105K 0.05% 91

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RiverPark Advisors's MIRM Position: Q1 2026 in Review

RiverPark Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 16% in Q1 2026, buying an estimated $26.5K and bringing the position to 2,014 shares worth $186K. The position accounts for 0.07% of the portfolio, ranked #90.

RiverPark Advisors first reported a position in MIRM in Q3 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • RiverPark Advisors held 2,014 shares of Mirum Pharmaceuticals worth $186K as of Q1 2026.
  • RiverPark Advisors bought 282 Mirum Pharmaceuticals shares in Q1 2026, an estimated $26.5K.
  • Mirum Pharmaceuticals made up 0.07% of RiverPark Advisors's portfolio in Q1 2026, its #90 holding.
  • RiverPark Advisors first reported a position in Mirum Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on RiverPark Advisors's 13F filing for Q1 2026, filed 14 May 2026.